The tool is the first electronic clinical outcome assessment product of its kind to fully integrate with RTSM
Wayne, PA – Bracket, a leading clinical trial technology and specialty services provider, will launch its next generation clinical outcomes platform, Bracket eCOASM 6.0, at the 52nd Annual DIA Meeting held on June 26 – 30 in Philadelphia, Pennsylvania. A demonstration of eCOA 6.0, the first electronic clinical outcome assessment product of its kind to fully integrate with RTSM, will be held at DIA Booth #715.
Bracket eCOA 6.0 is a flexible platform for electronic clinical outcomes assessments that is driving digitization in clinical trials. The platform integrates with industry-leading Samsung Galaxy smartphones and
Microsoft’s Surface Pro Windows tablets to support ePro, eClinRO, and eObsRO, and features fully integrated clinician and patient-facing tools, to ensure the experience is fully harmonized for any user.
“Bracket eCOA combines science and technology to collect patient information through smartphones or tablets, and ultimately achieve higher quality outcomes and efficiency in clinical trials,” said Jeff Kinell, CEO for Bracket. “We are pleased to launch eCOA 6.0 and continue demonstrating our commitment to paper-free clinical trials as we prepare for the mobile revolution.”
The platform’s integration with industry leading Clinical IRT solution, Bracket RTSM, enables subject questionnaires that trigger enrollment eligibility and randomization to kickoff schedule of reported outcomes entries. Its advisory services support scale design, development, licensing and validation, rater training and certification, clinical review and quality assurance, data analytics, and compliance tracking.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.